Ciro Franzese

List of Publications by Year
in descending order

122 papers	2,247 citations	218381 26 h-index	288905 40 g-index
123 all docs	123 docs citations	123 times ranked	3525 citing authors

#	Article	IF	Citations
1	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). Journal of Cancer Research and Clinical Oncology, 2015, 141, 1301-1309.	1.2	135
2	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technology in Cancer Research and Treatment, 2017, 16, 295-301.	0.8	80
3	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer, 2017, 17, 829.	1.1	77
4	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5â€‰years of follow-up. Radiation Oncology, 2018, 13, 234.	1.2	73
5	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
6	RapidPlan head and neck model: the objectives and possible clinical benefit. Radiation Oncology, 2017, 12, 73.	1.2	66
7	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiation Oncology, 2016, 11, 76.	1.2	59
8	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	1.1	58
9	Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. Journal of Neuro-Oncology, 2012, 108, 291-308.	1.4	50
10	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiotherapy and Oncology, 2019, 133, 220-226.	0.3	49
11	Low Prevalence of K-RAS, EGF-R and BRAF Mutations in Sinonasal Adenocarcinomas. Implications for Anti-EGFR Treatments. Pathology and Oncology Research, 2014, 20, 571-579.	0.9	46
12	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. Journal of Urology, 2019, 201, 70-76.	0.2	44
13	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. Radiotherapy and Oncology, 2019, 139, 83-86.	0.3	40
14	Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph nodeâ€‐negative breast cancer. Cancer, 2012, 118, 3236-3243.	2.0	39
15	RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategies. Radiation Oncology, 2019, 14, 187.	1.2	39
16	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlentherapie Und Onkologie, 2019, 195, 805-818.	1.0	36
17	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. International Journal of Gynecological Cancer, 2018, 28, 1507-1513.	1.2	35
18	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Research and Treatment, 2017, 49, 20-28.	1.3	34

#	Article	IF	Citations
19	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Lowâ€“Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	0.6	33
20	Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. European Journal of Surgical Oncology, 2017, 43, 735-742.	0.5	33
21	Hypofractionated stereotactic radiation therapy in skull base meningiomas. Journal of Neuro-Oncology, 2015, 124, 283-289.	1.4	31
22	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treatment Reviews, 2016, 50, 1-8.	3.4	30
23	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 111-121.	0.4	30
24	The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality. Frontiers in Oncology, 2020, 10, 7.	1.3	30
25	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treatment Reviews, 2021, 98, 102206.	3.4	30
26	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Medicine, 2018, 7, 4379-4386.	1.3	29
27	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: aÂmulti-institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 213-221.	1.0	29
28	Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1777-1783.	1.2	28
29	Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases. World Journal of Surgery, 2018, 42, 2651-2659.	0.8	27
30	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	1.2	27
31	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	2.0	27
32	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1293-1299.	1.2	26
33	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. Technology in Cancer Research and Treatment, 2018, 17, 153303381880388.	0.8	26
34	Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. Critical Reviews in Oncology/Hematology, 2019, 133, 163-170.	2.0	26
35	Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma. Current Oncology Reports, 2020, 22, 91.	1.8	25
36	Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1307-1313.	1.2	24

#	Article	IF	Citations
37	Imaging biomarkers in primary brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 597-612.	3.3	23
38	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 224.	1.2	22
39	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 614-621.	0.4	22
40	A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model. Lung Cancer, 2015, 90, 405-409.	0.9	21
41	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. BMC Cancer, 2014, 14, 833.	1.1	19
42	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlentherapie Und Onkologie, 2020, 196, 325-333.	1.0	19
43	Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy. BMC Cancer, 2016, 16, 362.	1.1	18
44	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with â€œcurativeâ€•intent. Lung Cancer, 2020, 141, 1-8.	0.9	17
45	Management of inflammatory breast cancer: Focus on radiotherapy with an evidence-based approach. Cancer Treatment Reviews, 2013, 39, 119-124.	3.4	16
46	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	0.6	16
47	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. British Journal of Radiology, 2015, 88, 20150111.	1.0	15
48	Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. Radiotherapy and Oncology, 2018, 127, 108-113.	0.3	15
49	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.4	15
50	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 163-169.	0.3	14
51	Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1301-1309.	1.2	14
52	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. Cancer Investigation, 2017, 35, 586-593.	0.6	14
53	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14
54	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast, 2018, 42, 31-37.	0.9	14

#	Article	IF	Citations
55	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	1.2	14
56	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkinâ€™s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	1.2	14
57	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 2021, 38, 527-537.	1.7	14
58	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. British Journal of Radiology, 2017, 90, 20170422.	1.0	13
59	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. World Neurosurgery, 2017, 105, 184-190.	0.7	13
60	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	0.8	13
61	Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study. Radiotherapy and Oncology, 2022, 167, 89-96.	0.3	13
62	Impact of a breathing-control system on target margins and normal-tissue sparing in the treatment of lung cancer: experience at the radiotherapy unit of Florence University. Radiologia Medica, 2014, 119, 13-19.	4.7	12
63	AÂradiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.. Strahlentherapie Und Onkologie, 2020, 196, 922-931.	1.0	12
64	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2289-2297.	1.2	12
65	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatmentâ€™s intensification?. Radiotherapy and Oncology, 2020, 150, 184-190.	0.3	12
66	Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis. Tumori, 2019, 105, 47-54.	0.6	11
67	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. Laryngoscope, 2020, 130, E163-E170.	1.1	11
68	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. British Journal of Radiology, 2020, 93, 20190627.	1.0	11
69	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 480-486.	1.1	10
70	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 885.	1.7	10
71	Randomized Phase III Trial Comparing Gamma Knife and Linac Based (EDGE) Approaches for Brain Metastases Radiosurgery: Results from the Gadget Trial. International Journal of Radiation Oncology Biology Physics, 2018, 102, S143-S144.	0.4	9
72	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. Clinical and Experimental Metastasis, 2020, 37, 565-573.	1.7	9

#	Article	IF	Citations
73	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2021, 147, 927-936.	1.2	9
74	Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis. Clinical and Experimental Metastasis, 2021, 38, 511-518.	1.7	9
75	Isolated chest wall implantation of non-small cell lung cancer after fine-needle aspiration: a case report and review of the literature. Tumori, 2012, 98, 126e-129e.	0.6	9
76	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. Nuclear Medicine Communications, 2018, 39, 951-956.	0.5	8
77	Critical appraisal of the potential role of intensity modulated proton therapy in the hypofractionated treatment of advanced hepatocellular carcinoma. PLoS ONE, 2018, 13, e0201992.	1.1	8
78	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. British Journal of Radiology, 2019, 92, 20190252.	1.0	8
79	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 608-616.	1.0	8
80	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. Strahlentherapie Und Onkologie, 2021, 197, 396-404.	1.0	8
81	Isolated Chest Wall Implantation of Non-Small Cell Lung Cancer after Fine-Needle Aspiration: A Case Report and Review of the Literature. Tumori, 2012, 98, e126-e129.	0.6	7
82	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. Strahlentherapie Und Onkologie, 2017, 193, 385-391.	1.0	7
83	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIROâ€Head and Neck working group. Oral Diseases, 2022, 28, 345-351.	1.5	7
84	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	1.0	6
85	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 628-635.	0.6	6
86	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlentherapie Und Onkologie, 2021, 197, 133-140.	1.0	6
87	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
88	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. British Journal of Radiology, 2017, 90, 20170022.	1.0	5
89	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	1.2	5
90	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3619-3625.	1.2	5

#	Article	IF	Citations
91	Radiotherapy Timing in the Treatment of Limited-stage Small Cell Lung Cancer: The Impact of Thoracic and Brain Irradiation on Survival. Tumori, 2014, 100, 289-295.	0.6	5
92	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. Strahlentherapie Und Onkologie, 2022, 198, 710-718.	1.0	5
93	Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patientsâ€™ selection. Clinical and Experimental Metastasis, 2022, 39, 449-457.	1.7	5
94	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. Clinical Lung Cancer, 2020, 21, 86-93.	1.1	4
95	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. Practical Radiation Oncology, 2021, 11, e329-e338.	1.1	4
96	Discrepancies between UICC and AJCC TNM classifications for oral cavity tumors in the 8th editions and following versions. European Archives of Oto-Rhino-Laryngology, 2022, 279, 527-531.	0.8	4
97	Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer. Journal of Chemotherapy, 2011, 23, 36-39.	0.7	3
98	Pegylated Liposomal Doxorubicin (Caelyx^{Â®}) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines. Journal of Chemotherapy, 2011, 23, 158-162.	0.7	3
99	Limited-Stage Small-Cell Lung Cancer Treated with Early Chemo-Radiotherapy: The Impact of Effective Chemotherapy. Tumori, 2012, 98, 53-59.	0.6	3
100	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1937-1945.	1.2	3
101	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. Reports of Practical Oncology and Radiotherapy, 2021, 26, 101-110.	0.3	3
102	Radiotherapy timing in the treatment of limited-stage small cell lung cancer: the impact of thoracic and brain irradiation on survival. Tumori, 2014, 100, 289-95.	0.6	3
103	The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technology in Cancer Research and Treatment, 2020, 19, 153303382098041.	0.8	2
104	Accuracy of f<scp>ineâ€needle</scp> aspiration cytology in detecting cervical node metastasis after radiotherapy: Systematic review and metaâ€analysis. Head and Neck, 2021, 43, 987-996.	0.9	2
105	The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. Radiotherapy and Oncology, 2021, 156, 49-55.	0.3	2
106	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. Acta OncolÃ³gica, 2022, 61, 553-559.	0.8	2
107	Stereotactic radiotherapy for liver oligometastases. Reports of Practical Oncology and Radiotherapy, 2022, 27, 32-39.	0.3	2
108	Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report. Tumori, 2013, 99, e233-6.	0.6	2

#	Article	IF	Citations
109	Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario. International Journal of Clinical Oncology, 2021, 26, 1777-1783.	1.0	1
110	Limited-stage small-cell lung cancer treated with early chemo-radiotherapy: the impact of effective chemotherapy. Tumori, 2012, 98, 53-9.	0.6	1
111	Outcome Evaluation of Patients With Diagnosed WHO Grade III Glioma Treated According to the Molecular Profile, the Histology, and the Extent of Resection (EOR). International Journal of Radiation Oncology Biology Physics, 2016, 96, E109.	0.4	0
112	Role of Stereotactic Body Radiation Therapy With Volumetric Modulated Arc Therapy Technique and FFF Beams for Abdomino-Pelvic Lymph Node Metastases in Oligometastatic Patients. International Journal of Radiation Oncology Biology Physics, 2016, 96, E142-E143.	0.4	0
113	EP-1442: Oligometastatic colorectal cancer in elderly patients: role of stereotactic body radiation therapy. Radiotherapy and Oncology, 2016, 119, S669-S670.	0.3	0
114	PV-0511: Hypofractionated VMAT for early stage breast cancer: acute toxicity and cosmesis in 840 patients. Radiotherapy and Oncology, 2016, 119, S241-S242.	0.3	0
115	EP-1279: SABR in inoperable liver oligometastatic patients and radioresistant primary tumors.. Radiotherapy and Oncology, 2016, 119, S601-S602.	0.3	0
116	P2.05-008 Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From â€œRadioresistantâ€•Histologies?. Journal of Thoracic Oncology, 2017, 12, S1035.	0.5	0
117	EP-1343: Is stereotactic body radiation therapy a viable option for elderly patients with prostate cancer?. Radiotherapy and Oncology, 2017, 123, S720-S721.	0.3	0
118	EP-1409: Prospective study of hypofractionated radiotherapy for elderly patients with High Grade Glioma. Radiotherapy and Oncology, 2017, 123, S753-S754.	0.3	0
119	A Multi-Institutional Analysis on the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Lymph Node Oligometastases in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 105, E298.	0.4	0
120	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. Cancer Management and Research, 2021, Volume 13, 7009-7031.	0.9	0
121	Response to letter to the editor regarding C Franzese et al. â€œMetastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancerâ€• Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	0
122	Role of SBRT with VMAT technique and FFF beams for lymph-node metastases in oligometastatic patients from genitourinary malignancies.. Journal of Clinical Oncology, 2016, 34, e16136-e16136.	0.8	0